News

PD-L1 Expression: Predicting Immunotherapy Response in Urothelial Carcinoma

Researchers Construct Prognostic Nomogram for Use in Patients With Bladder Cancer and Lung Metastasis

Can BCG Vaccination Induce Immune Responses Against COVID-19?

Finding Genetic Clues in Cats, Dogs, and Cows to Treat Human Bladder Cancer

The Changing Treatment Landscape in Urothelial Carcinoma: Focus on PARP Inhibitors

Surgical Strategies to Reduce Recurrence of Upper Tract Urothelial Carcinoma

Can the Antidepressant Fluoxetine Promote Sensitivity to Cisplatin in Bladder Cancer?

Researchers Explore How Sexual Diversity May Impact Bladder Cancer

Effects of Multiple Risk Factors on Cancer-Specific Survival in Non–Muscle-Invasive Bladder Cancer

ASCOBT 2023: Nectin-4 Expression and the Tumor Microenvironment in Bladder Cancer

$11.2 Million Grant From NCI to Fund Research on Sex Differences in Bladder Cancer

ASCOBT 2023: Predicting Immunotherapy Responses With VI-RADS Scores in Muscle-Invasive Bladder Cancer

Ongoing Trial to Evaluate Erdafitinib in FGFR3-Mutated Non–Muscle-Invasive Bladder Cancer

Efficacy of Pembrolizumab Monotherapy and Histologic Subtype of Advanced Urothelial Cancer

Comparing the Cost of Robot-Assisted Versus Open Radical Cystectomy for Bladder Cancer

Long-Term Outcomes With Pembrolizumab Plus Chemoradiotherapy in Urothelial Bladder Cancer

Advanced Bladder Cancer: Combination Therapy of Copanlisib and Avelumab Focus of Phase II Trial

Can Personalized Whole-Genome Sequencing Identify MRD Rates in Muscle-Invasive Bladder Cancer?

Does CDH1 Mutation Status Affect Treatment Efficacy in Urothelial Bladder Cancer?

Durability of Complete Responses in Patients Treated With Pembrolizumab for Advanced Urothelial Cancer

Long-Term Safety Analyses of Maintenance Avelumab From JAVELIN Bladder 100

Do Survival Outcomes Vary Between Micropapillary and Classic Urothelial Cancers?

ASCO 2023: Comparing Types of Lymphadenectomy in Surgical Treatment of Muscle-Invasive Urothelial Cancer

ASCO 2023: Phase III Trial Offers Insights on Prevalence of FGFR3 Alterations in Invasive Urothelial Cancer

ASCO 2023: IMvigor130 Trial Update With Atezolizumab Plus Chemotherapy for Metastatic Urothelial Cancer

ASCO 2023: Some Patients With Metastatic Urothelial Cancer May Benefit From Erdafitinib Over Chemotherapy

ASCO 2023: 5-Year Survival Data on Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer

ASCO 2023: How Many Cycles of Neoadjuvant Chemotherapy Is Enough for Muscle-Invasive Bladder Cancer?

ASCO 2023: Final NORSE Trial Results on Erdafitinib Plus Cetrelimab in Metastatic Urothelial Carcinoma

ASCO 2023: Long-Term Update on Use of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma

ASCO 2023: Factors Affecting Recurrence of Bladder Cancer After Transurethral Resection

CT Analysis of Inflammatory Myofibroblastic Bladder Tumors

What Can Optimizing Surveillance Protocols Do for Patients With Bladder Cancer?

BCG After Transurethral Resection of Bladder Cancer: How Body Composition May Impact Outcomes

Investigational Chemotherapy Delivery System Advances Treatment of BCG-Unresponsive Bladder Cancer

Around the World, Early Recurrence of Bladder Cancer Differs After Transurethral Resection

Oncolytic Vaccine Plus Pembrolizumab for BCG-Unresponsive Bladder Cancer

USC Surgeons Take Steps Toward the First-in-Human Bladder Transplantation

AUA 2023: Does Prior Radiation Therapy Impact BCG Outcomes in High-Risk, Bladder Cancer?

AUA 2023: Reducing Urinary Tract Infections After Flexible Cystoscopy

Using Molecular Subtyping to Predict Response to Immunotherapy in Urothelial Cancer

Novel Gene Signature for Bladder Cancer: Predicting Prognosis and Therapeutic Response

AACR 2023: Biomarkers May Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer

AACR 2023: IHC Subtypes Offer Prognostic Hint in Muscle-Invasive Bladder Cancer

NCCN 2023: Update on Emerging Therapies for Bladder Cancer

AACR 2023: Is a Cell-Free DNA Assay Clinically Effective in Urothelial Carcinoma?

Lysosomal Positioning in Bladder Cancer With Hyperactivated Transcription Factor EB

Use of Noncoding Mutation Hotspots as a Noninvasive Tool for Bladder Cancer Detection

FDA Brief: Antibody-Drug Conjugate and PD-1 Inhibitor Combination Granted Accelerated Approval in Advanced Urothelial Cancer

Sequential HER2-Targeted Antibody-Drug Conjugate in Resistant Metastatic Bladder Cancer: Case Study

PRR11 Expression in Bladder Urothelial Carcinoma: Prognostic and Therapeutic Implications